UK Pharmaceutical company AstraZeneca announced today in a press release they will be providing 400M of their AZD1222 COVID-19 vaccines to European nations starting at the end of 2020.

"This agreement will ensure that hundreds of millions of Europeans have access to Oxford University’s vaccine following approval." said AstraZeneca CEO Pascal Soriot, "With our European supply chain due to begin production soon, we hope to make the vaccine available widely and rapidly. I would like to thank the governments of Germany, France, Italy and the Netherlands for their commitment and swift response."

When are we getting the vaccine? See our vaccine tracker where we stay up to date every day on companies manufacturing the COVID-19 vaccine.

The agreement was reached with Europe's Inclusive Vaccines Alliance (IVA) which is lead by Germany, France, Italy, and the Netherlands. In order to reach this milestone, the company is expanding their production capabilities to meet the needs globally and in Europe.

Previously, AstraZeneca completed an agreement with the Serum Institute of India to supply 1 billion doses for low- and middle income countries.

AstraZeneca is also working with Gavi, the vaccine alliance to produce 700M doses for low- and middle-income countries.

Yesterday, the company announced a partnership with Emergent Bio to produce vaccines in support of the US's Operation Warp Speed, which aims to procure vaccines by the end of the year in the United States.